INOVIO to Present at Upcoming Scientific and Investor Conferences

Core Insights - INOVIO is focused on developing DNA medicines for HPV-related diseases, cancer, and infectious diseases, and will present at several upcoming conferences to share new data on its lead candidate INO-3107 [1][4] Conference Presentations - INOVIO will participate in the Citizens JMP Life Sciences Conference on May 8, featuring a fireside chat format [2] - At the European Laryngological Society Annual Congress on May 9, INOVIO will present data showing that INO-3107 generates a targeted immunologic response, resulting in surgery reduction for 81% of adults with recurrent respiratory papillomatosis in the first year [2] - The American Society of Gene and Cell Therapy will host a poster abstract session on May 13, discussing the successful treatment of recurrent respiratory papillomatosis with INO-3107, regardless of papilloma microenvironment and molecular subtype [2] - An oral presentation at the ABEA program during the COSM on May 15 will focus on the durability and long-term clinical effects of INO-3107 in treating recurrent respiratory papillomatosis caused by HPV types 6 and 11 [3] Company Overview - INOVIO is a biotechnology company that specializes in the design and delivery of innovative DNA medicines, aiming to empower the body to produce its own disease-fighting tools [4]